Our Clinical Studies

We design and conduct clinical trials for dietary supplements, cosmetics, and medical devices based on substances compliant with the European Regulation 2017/745 (MDR – Medical Device Regulation), and continuously collect market data to ensure the safety of our products.

We manage and conduct clinical studies on products, leveraging our extensive internal cross-disciplinary expertise. This enables us to collaborate effectively with various stakeholders: participants, ethics committees, competent authorities, scientific and academic societies. We constantly stay updated on increasingly stringent international regulations and guidelines to ensure the highest compliance and quality.

Clinical Study of Asthenic Children

The study of 71 abstinent children showed that the Cresko supplement (iron, royal jelly, glutamine, B vitamins) significantly improved their psychosocial and emotional state. Efficacy correlated positively with age, treatment duration, and weight gain, with no short-term adverse events.

GFI Publishes Clinical Trial on Infant Colic

The clinical trial of Rilefast Ace, a medical device based on simethicone and silicon dioxide, showed a significant reduction in infant colic symptoms. Treated infants experienced less pain and crying, with particularly positive results in cases of greater initial distress.

Rilefast CE and infant colic: ultrasound analysis of intestinal gas

This trial integrates previous research on the effectiveness of the Rilefast CE medical device containing simethicone and silica dioxide in treating infant colic. It evaluates the results via ultrasound to measure intestinal gas content.

Clinical Study on Lung Conditions

This clinical study evaluated Broncofurin, an integrative supplement with NAC, Marshmallow, Sundew, Red Poppy, and Vitamin C, aiming to enhance lung function and reduce respiratory symptoms in elderly patients with stable COPD. Findings indicate a significant symptom improvement after 1 and 3 months of administration.

Study on the Effectiveness of Simethicone in Water for the Treatment of Gastrointestinal Disorders in Newborns

The clinical study on Secol, a medical device based on Simethicone in water, has demonstrated a significant reduction in gastrointestinal symptoms in infants. After two weeks of treatment, a marked improvement in abdominal pain, bloating, and aerophagia was observed, with a positive impact on the quality of life of the young patients.

Revaginal Gel: Clinical Efficacy for Vaginal Discomfort

Our clinical study confirms its effectiveness in treating post-menopausal vulvovaginal disorders, improving comfort and quality of life. Discover Revaginal Gel, a clinically tested vaginal gel.

Clinical Study: Vaginal Tissue Regeneration

Gruppo FarmaImpresa presents the results of the clinical study on the Revaginal Ovules vaginal medical device, formulated to regenerate vulvovaginal tissues and improve female intimate health. Thanks to a composition based on hyaluronic acid, lactic acid, vitamins, and plant extracts, Revaginal ovules have demonstrated clinically significant efficacy in reducing dryness, burning, irritation, and sexual pain.

Clinical Study on Fertilifast – Nutraceutical support for male infertility

Gruppo FarmaImpresa conducted an observational clinical study to evaluate the effectiveness of Fertilifast in improving seminal parameters in men affected by idiopathic infertility for more than 12 months. After 90 days of treatment, results showed a statistically significant improvement in total and progressive sperm motility, an increase in sperm concentration, and a reduction in leukocyte count, an indicator of decreased oxidative stress and inflammation.

Clinical Study on Revilan – Immune support in children with recurrent respiratory infections

Gruppo FarmaImpresa conducted a multicenter observational clinical study involving 270 children diagnosed with recurrent respiratory infections (RRI) to evaluate the effectiveness of Revilan in preventing respiratory tract infections. After 3 months of treatment, the results demonstrated a statistically significant reduction (p < 0.001) in respiratory infections, fever days, antibiotic use, and school and parental work absences.

Clinical Study on Lattawin Ovules – Clinically proven efficacy in vulvovaginal disorders

Gruppo FarmaImpresa conducted an observational clinical study to evaluate the effectiveness of Lattawin Ovules, a vaginal medical device, in the treatment of vulvovaginal disorders. After 4 weeks of treatment, patients showed a statistically significant reduction in symptoms assessed using the validated Vulvovaginal Symptoms Questionnaire (VSQ), with marked improvement in dryness, itching, burning, irritation, and dyspareunia.

Clinical Study on Reflucalm – Effectiveness in the treatment of gastroesophageal reflux in infants

Gruppo FarmaImpresa conducted a multicenter observational clinical study to evaluate the effectiveness of Reflucalm, a medical device indicated for the treatment of gastroesophageal reflux in infants. After 4 weeks of treatment, results showed a statistically significant reduction in symptoms assessed using the validated I-GERQ-R questionnaire, with marked improvement in regurgitation, crying, irritability, and feeding difficulties.

Clinical Study on Reflucalm – Efficacy in gastroesophageal reflux disease (GERD) in adults

Gruppo FarmaImpresa conducted a multicenter observational clinical study in adult patients affected by gastroesophageal reflux disease (GERD) to evaluate the effectiveness of Reflucalm, a medical device designed to protect the esophageal mucosa. After 4 weeks of treatment, results showed a statistically significant reduction in symptoms, assessed using the validated GERD-HRQL questionnaire, with a marked improvement in quality of life.

Clinical study on Artox Syringes – statistically significant improvement in pain, stiffness and function in osteoarthritis

Gruppo FarmaImpresa conducted an observational clinical study on 20 patients with knee and hip osteoarthritis to evaluate Artox Syringes. After 4 weeks, the mean WOMAC score decreased significantly from 57.1 to 19.9 (p < 0.001), with a clinically meaningful improvement in 95% of patients and no adverse events reported.

Clinical Study on Aleman – significant improvement of constipation in Parkinson’s patients

A 6-week observational clinical study on 20 Parkinson’s patients with constipation (Rome II criteria) evaluated Aleman (FOS + D-mannitol). After 30 days, weekly bowel movements nearly doubled (IR 1.97; p < 0.001), laxative use decreased markedly (IR 0.39; p = 0.004), and subjective discomfort improved significantly (−3.5 points; p < 0.001).

Clinical Study on Caregyn Ovules – symptom remission in over 89% of patients with vaginal dryness and altered pH

A clinical study on 19 women (18–72 years) with vaginal dryness and altered pH evaluated Caregyn Ovules, a vaginal medical device (FT.CE.111). After 1 week, the mean VSQ score dropped from 5.11 to 0.16 (Δ −4.95; p < 0.001), and 89% of patients achieved complete symptom remission (VSQ = 0), with improvements in itching, burning, pain, dryness, and intimate discomfort.

Rinofast: clinical efficacy in nasal congestion

The observational clinical study on Rinofast, a medical device for the treatment of nasal congestion and symptoms associated with rhinitis and rhinosinusitis, demonstrated a significant reduction in symptoms assessed through the SNOT-22 scale. Patients showed improvements in breathing, nasal secretions, sleep quality, and overall well-being, with statistically significant results